Aurobindo receives FDA nod for 2 generics
Aurobindo has obtained the Food and Drug Administration’s blessing for bromfenac ophthalmic solution 0.09%.
The medication is the generic of Bausch & Lomb’s Bromday.
It is indicated for postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
[Read more: Aurobindo obtains FDA OK for generic Lioresal]
Bromfenac ophthalmic solution has a market value of roughly $1.6 million for the 12 months ending February 2022, according to IQVIA.
Aurobindo also has received the FDA’s nod for clobazam oral suspension, 2.5mg/mL.
The product is the generic of Lundbeck’s ONFI.
This medication is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years old and older.
[Read more: Aurobindo obtains FDA nod for generic Tricor]
Clobazam oral suspension has a market value of roughly $3.6 million for the 12 months ending January 2022, according to IQVIA.